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PreventionAbstract Trauma is the leading cause of temporomandibular joint (TMJ) bony ankylosis. The
treatment of the condition poses a signiﬁcant challenge because of the high incidence of recurrence.
We previously proposed a new view that the development of traumatic TMJ bony ankylosis may be
a course similar to hypertrophic nonunion, and the ensuing animal experiments preliminarily ver-
iﬁed this view through histological analysis and molecular biology examination. In view of the sim-
ilarity between bone healing and bony ankylosis, and the importance of recruitment and
differentiation of mesenchymal stem cells (MSCs) during the course of bone healing, it is reasonable
to select MSCs as the breakthrough point for prevention of bony ankylosis. Recent studies reveal
that ﬁbroblast growth factor 21 (FGF21), a key mediator of peroxisome proliferator-activated
receptor-c (PPARc), can promote adipocyte differentiation, inhibit osteoblast differentiation of
MSCs and stimulate osteoclast activity by activation of PPARc. Therefore, we hypothesize that
local FGF21 injection may prohibit the onset of traumatic TMJ bony ankylosis through formation
of a fat pad separating the condyle from the glenoid fossa, inhibition of new bone formation and
promotion of bone resorption in the joint space, which thus may be a potential novel treatment for
TMJ bony ankylosis.
ª 2013 Tehran University of Medical Sciences. Published by Elsevier Ltd.Health
D license.
24 S.-X. Liang, Y.-B. YanIntroduction
Post-traumatic temporomandibular joint (TMJ) bony ankylo-
sis is regarded as bony fusion between the two injured articular
surfaces [1]. It is a severe disability that results in restricted
mouth opening and masticatory difﬁculty. So far, surgery is
the only method to treat this condition. Due to the difﬁculty
of operation and the recurrence rate of 9–20% [2–4], surgical
treatment of bony ankylosis is still a considerable challenge
for craniomaxillofacial surgeons. Prevention of the develop-
ment of traumatic TMJ bony ankylosis may be the most effec-
tive treatment modality. However, no effective method of
prevention has been reported. Finding a novel, effective,
non-surgical treatment for bony ankylosis seems quite
important.
The development of traumatic TMJ bony ankylosis: a course
similar to hypertrophic nonunion?
The precise pathogenic process and molecular mechanism of
the traumatic TMJ bony ankylosis remain ill-deﬁned [5]. Our
understanding of the pathogenesis of the disease derives
mainly from several popular hypotheses, including organisa-
tion and ossiﬁcation of the haematoma [1,6], distraction osteo-
genesis of the lateral pterygoid muscle [7,8] and genetic
predisposition [9]. Recently, through reviewing the literature,
we found that the occurrence condition for traumatic TMJ
bony ankylosis was in fact to establish the microenvironment
for the bone healing of the two articular surfaces [10–12] and
that bone graft in the joint or restricted jaw movement can
accelerate the process of ankylosis [13–15]. Taking into ac-
count the inhibitory role of the opening movement in bone for-
mation in the joint space [16], we proposed a new view that the
development of traumatic TMJ bony ankylosis was a compro-
mised bone healing course, especially a course similar to hyper-
trophic nonunion [17], which was a supporter to the hypothesis
of ossiﬁcation of the haematoma.
To test this new opinion, a sheep model of TMJ bony anky-
losis was established by mimicking the traumatic microenvi-
ronment of sagittal condylar fracture [18]. The histological
analysis of the animal model demonstrated that endochondral
ossiﬁcation was the main type of bone formation during the
formation of bony ankylosis and a prolonged chondral phase
was revealed compared to condylar fracture healing, which
indicates a similarity between bony ankylosis and compro-
mised bone healing [18].
Based on the established animalmodel, the endogenousmes-
senger RNA (mRNA) expression of a series of genes regulating
cartilage formation, bone formation and endochondral ossiﬁca-
tion was examined. We found a continuous up-regulation trend
in the gene expression of Wnt1, Wnt2b, Wnt3a, b-catenin,
Sfrp1, Lrp6, Lef1, CyclinD1 and Runx2 at 3 and 6months com-
pared with 1 month, which indicated that the Wnt signalling
that played important roles in fracture healing was also acti-
vated during the formation of TMJ bony ankylosis [19].
Through examining the differential expression among ﬁbrous
ankylosis, bony ankylosis and condylar fracture by real-time
polymerase chain reaction (PCR), we found that the mRNA
expression levels of Wnt5a, b-catenin, Lef1, Runx2, Osterix,
Sox9, Col10a1, Alp, Ocn, Bmp2 and Bmp7 in bony ankylosed
callus were inclined to be higher than those in ﬁbrous ankylosedcallus, but lower than those in fracture callus at several time
points [20]. These results demonstrated that the development
of bony ankylosis was a compromised bone healing, especially
a course that was similar to the hypertrophic nonunion, with
low activity of osteogenesis in the joint space in the molecular
level [20]. Another study by Xiao et al. [21] has isolated and
identiﬁed mesenchymal stem cells (MSCs) from the radiolucent
zone of human bony ankylosed specimens, and showed that
MSCs in the radiolucent zone possessed a lower proliferation
and osteogenic differentiation capacity compared with those
from normal mandibular bone marrow.
In summary, so far, a series of clinical and experimental
studies have preliminarily veriﬁed our view regarding the path-
ogenesis of traumatic TMJ bony ankylosis and also provided
important information for exploring suitable methods to pre-
vent the development of the disease.
PPARc and MSCs
In view of the similarity between bone healing and bony anky-
losis, and the importance of recruitment and differentiation of
MSCs during the course of bone healing, it is reasonable to se-
lect MSCs as the breakthrough point for prevention of bony
ankylosis. It is well known that MSCs can differentiate into
different cell lineages under speciﬁc transcription factors, such
as differentiation into osteoblasts determined by Runx2/Oster-
ix and differentiation into chondrocytes determined by Sox5/6/
9 [22]. Peroxisome proliferator-activated receptor-c (PPARc)
is the key transcription factor for the differentiation of MSCs
into adipocytes [23]. PPARc is also the molecular switch be-
tween the osteogenic and adipogenic pathways [24]. Overex-
pression of PPARc in MSCs can not only suppress the
expression of Runx2 and the osteoblast differentiation but also
promote their terminal differentiation into adipocytes [25]. Re-
cent studies reveal that PPARc can inhibit osteoblastogenesis
from bone-marrow MSCs and promote osteoclast differentia-
tion from haematopoietic stem cells [26,27], suggesting that
PPARc plays important roles in skeletal homeostasis.
FGF21, a key mediator of PPARc
Fibroblast growth factor-21 (FGF21) is an atypical member of
the FGF family. It activates cell signalling through binding
with the classic FGF receptors complexed with b-Klotho in
the cell surface [28]. FGF21 has broad metabolic actions,
mainly in regulation of glucose and lipid metabolism. It can in-
crease energy expenditure, enhance insulin sensitivity and re-
duce body weight when administered to diabetic rodents and
monkeys [29,30].
Recent studies on the FGF21-knockout mice reveal that
FGF21 can activate PPARc by inhibition of its sumoylation,
promoting the differentiation of MSCs of the adipose tissue
into adipocytes while inhibiting osteoblast differentiation
[31]. FGF21 can also promote the differentiation of MSCs of
the bone marrow into adipocytes through the same mechanism
[32]. In addition, FGF21 can stimulate osteoclastogenesis and
bone resorption by activation of PPARc and change of the ra-
tio of receptor activator of NF-kappaB ligand/osteoprotegerin
(RANKL/OPG) [32]. These ﬁndings demonstrate that FGF21
is a key factor regulating the physiological and pharmacolog-
ical functions of PPARc.
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Our hypothesis is that FGF21 may be a potential drug for pre-
venting the development of traumatic TMJ bony ankylosis. On
the one hand, FGF21 can stimulate the differentiation of the
MSCs in the joint space to adipocytes while suppressing its
osteoblast differentiation, thus resulting in the formation of
a fat pad separating the condyle from the glenoid fossa and
inhibiting new bone formation meanwhile. On the other hand,
FGF21 can activate PPARc and change the RANKL/OPG ra-
tio, thus promoting osteoclastogenesis and bone resorption in
the joint space.
Evaluation of the hypothesis
Traumatic TMJ bony ankylosis remains an enigma, partly due
to the ambiguous recognition of the nature of the condition
and the lack of understanding of molecular mechanisms under-
lying the disease onset and progression. We believed that the
nature of the disease was a compromised bone healing under
the interference of the opening movement, and the ensuing
experiments preliminarily veriﬁed this notion [18–21]. There-
fore, theoretically all methods of inhibiting bone formation
or fracture healing, such as non-steroidal anti-inﬂammatory
drugs [33], low-dose irradiation [34,35], antagonists of BMP
and Wnt signalling pathways [36,37] and so on, may be bene-
ﬁcial to the prevention of TMJ bony ankylosis. However, it
can be anticipated that the outcomes of the above-mentioned
strategies may only convert bony ankylosis into ﬁbrous anky-
losis rather than prevent the onset of bony ankylosis because
abundant ﬁbrous tissue will grow into the joint space while
bone formation is inhibited.
However, if we take an alternative approach, namely inhi-
bition of bone formation and simultaneous stimulation of
the adipocyte differentiation of the MSCs, the outcome may
be different. The fat pad will form in the joint space and sep-
arate the condyle from the glenoid fossa, serving as a physical
barrier and a mechanical buffer like a normal disc, ultimately
prohibiting the onset of bony ankylosis. Experimental studies
have observed ‘adipogenic healing’ at the nonunion site, indi-
cating that the adipose tissue can be present during fracture
healing [38,39]. In addition, clinical studies have demonstrated
that autologous fat grafts placed around the TMJ can prevent
the postoperative recurrence of ankylosis [40,41]. Therefore,
FGF21, the key mediator of PPARc, may be a promising drug
speciﬁc for prevention of the TMJ bony ankylosis.
Testing the hypothesis
Use of recombinant adenoviruses (Ad) to express secreted
growth factors represents a powerful method in studies with
experimental animals [42]. This strategy can produce a large
amount of recombinant protein with a single injection. Hence,
we can construct an adenoviral expression of FGF21 (Ad-
FGF21) and inject it into the joint space of the sheep which
are induced into TMJ bony ankylosis as previously described
[18], then observe whether adipose tissue forms and whether
this handling can prevent the progress of bony ankylosis or
not. If this hypothesis proves to be true, local FGF21 injection
will be a novel treatment for bony ankylosis without surgical
resection in the future.Conﬂict of interest statement
None declared.Overview box
First Question: What do we already know about the
subject?
1. Traumatic TMJ bony ankylosis may be a course simi-
lar to hypertrophic nonunion.
2. FGF21 can promote adipocyte differentiation, inhibit
osteoblast differentiation of MSCs and stimulate
osteoclast activity by activation of PPARc.
Second Question: What does your proposed theory add
to the current knowledge available, and what beneﬁts does
it have?
FGF21 may prohibit the onset of traumatic TMJ bony
ankylosis and thus may be a potential novel treatment for
bony ankylosis.
Third question: Among numerous available studies, what
special further study is proposed for testing the idea?
An interference experiment using adenoviral expres-
sion of FGF21 (Ad-FGF21) can be performed in the
established animal model.References
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